WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, introduced the Medicaid VBPs for Patients (MVP) Act alongside Congressman Jake Auchincloss (MA-04), Congressman John Joyce, M.D. (PA-13), Congressman Scott Peters (CA-50), Congresswoman Mariannette Miller-Meeks (IA-02), and Congressman Don Davis (NC-01), . This legislation would improve vulnerable populations’ access to innovative treatments and cures by enabling states to voluntarily enter value-based purchasing (VBP) agreements, which tie the cost of treatments to patient outcomes.
“I’m pleased to reintroduce my bipartisan MVP Act to expand access to innovative, lifesaving treatments for vulnerable Americans with rare diseases. This transformative legislation would give states the flexibility to offer high-cost therapies for rare diseases without raising taxes or cutting other state programs,” said Chairman Brett Guthrie (KY-02). “The bill’s payment model will incentivize value-based payment arrangements, empowering state Medicaid programs to help vulnerable patients gain access to potentially life-changing treatments, like gene and cell therapies.”
“The science on cell and gene therapies has now outpaced the policy & payment models. That’s going to lead to frustration for patients with rare diseases, including children, who can see cures in the making but cannot access them. This bill helps ensure everyone can access cutting edge gene therapies. It also helps ensure that medicines with value are rewarded, while treatments that don’t work don’t add cost to the health system,” said Congressman Jake Auchincloss.
“The MVP Act represents a profound step forward in delivering life-changing treatments to the patients who need them most. By advancing value-based payments, we can guarantee that the most vulnerable in our society have access to high-cost therapies and cures for rare diseases, while protecting taxpayers and vital federal programs. This bipartisan effort exemplifies a shared commitment to improving health outcomes by ensuring that Medicaid effectively serves patients and families across the country,” said Congressman John Joyce, M.D.
“Today, potentially curative therapies give hope to San Diegans with certain kinds of cancers, hemophilia, spinal muscular atrophy, sickle cell disease, hereditary blindness, and Duchenne muscular dystrophy. However, people with Medicaid struggle to access these transformative treatments because of their high costs. I look forward to passing the Medicaid VBPs for Patients (MVP) Act, which will help state Medicaid programs enter value-based payment agreements and give states the flexibility they need to pay for these medicines based on patient outcomes,” said Congressman Peters.
“This legislation strengthens America’s healthcare system by lowering costs, expanding patient access, and reinforcing domestic medical manufacturing,” said Dr. Mariannette Miller-Meeks. “By supporting innovation and bolstering our supply chain here at home, this bill helps ensure patients receive affordable, high-quality care while protecting American jobs and competitiveness.”
“Eastern North Carolinians with rare diseases and their families deserve access to the latest lifesaving treatments close to home, without unnecessary delays or barriers to care. The MVP Act would give states the purchasing flexibility they need to expand access to cutting-edge therapies and innovative treatments, helping ensure these breakthroughs are within reach for the families who depend on them most,” said Congressman Don Davis.
BACKGROUND:
– The MVP Act would modernize the Medicaid Drug Rebate Program, allowing manufacturers to submit multiple best prices to state Medicaid programs and for state Medicaid programs to voluntarily enter VBP arrangements with drug manufacturers for these therapies.
– This would better align incentives in the health care system by tying the amount manufacturers receive for high-cost drugs to the effectiveness of the treatment, enabling state Medicaid programs to offer the most advanced treatment options to those battling rare diseases.
Click HERE to read the bill text.
